Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIAO vs EPREX in Renal Anemia
NCT02947438Phase 3Completed
- Sponsor
- 3SBio
- Start
- Dec 2015
- Primary completion
- Oct 2021
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of epoetin alfa in anemia of chronic kidney disease (2 arms), sponsored by 3SBio. Primary endpoints: Mean absolute change in haemoglobin level at 6 months and Mean absolute change in weekly epoetin dosage per kg body weight at 6 months. Started Dec 2015; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT02947438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947438.